Janssen Search
Search results
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Aug 27, 2024 Belgium Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI [1], [2], [3], [4] Amivantamab ...
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
Feb 13, 2023 United States Updated data from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer will be featured RARITAN, N.J., Feb. 13, 2023 -- ...
Cautions Concerning Forward-Looking Statements
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" regarding the potential acquisition of Momenta. The reader is cautioned not to rely on these forward-looking statements. These statements are ...
Phase 3 MARIPOSA-2 Study Shows RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or after Osimertinib
Oct 23, 2023 Spain Phase 3 MARIPOSA-2 Study Shows RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFR-Mutated Non-Small Cell ...
Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cel
Jul 17, 2023 United States First Phase 3 study to demonstrate clinically meaningful results versus standard of care in a newly diagnosed exon 20 population, a patient population with high unmet medical need RARITAN, New Jersey, July 17, 2023 – The ...
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
Jun 14, 2024 At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM (14 June 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated ...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
Jul 30, 2024 Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ® as a foundational frontline therapy in multiple ...
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma
Dec 12, 2023 United States DARZALEX FASPRO ®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen First presentation of data from Phase 3 PERSEUS study highlighted ...
Update on Janssen’s BACE Inhibitor Program Regarding the Dominantly Inherited Alzheimer’s Network Trial (DIAN-TU)
Article Type: Neuroscience Update on Janssen’s BACE Inhibitor Program Regarding the Dominantly Inherited Alzheimer’s Network Trial (DIAN-TU) The statement below is an update to our May 17, 2018, announcement found here. Titusville, New Jersey, May 25, ...
Change Is Coming
Change is Coming. It’s About Time, and We are Ready. Having worked at the Johnson & Johnson Family of Companies for almost 25 years, I've seen first-hand the commitment my company has had to positive change. Because of this, I’m excited to ...